Unsustainable drug prices : hearing before the Committee on Oversight and Reform, House of Representatives.
Saved in:
| Online Access: |
Online Access |
|---|---|
| Corporate Author: | |
| Other title: | Title for parts I and II: Unsustainable drug prices : testimony from the CEOs. Title for part III: Unsustainable drug prices : testimony from AbbVie CEO Richard Gonzalez. |
| Format: | Government Document eBook |
| Language: | English |
| Published: |
Washington :
U.S. Government Publishing Office,
2020-2021.
|
| Subjects: |
| Item Description: | "One Hundred Sixteenth Congress, second session"--Pts. 1 and 2. "One Hundred Seventeenth Congress, first session"--Pt. 3. Access ID (govinfo, pt. 1): CHRG-116hhrg41982. Access ID (govinfo, pt. 2): CHRG-116hhrg41983. "Serial number 116-122"--Pt. 1. "Serial number 116-123"--Pt. 2. "Serial number 117-22"--Pt. 3. "September 30, 2020"--Pt. 1. "October 1, 2020"--Pt. 2. "May 18, 2021"--Pt. 3. |
|---|---|
| Physical Description: | 1 online resource (3 volumes) |
| Participant or Performer: | Hearing witnesses (pt. 1): Mr. Mark Alles, Former Chairman of the Board and Chief Executive Officer, Celgene Corporation; Dr. Giovanni Caforio, Chairman of the Board and Chief Executive Officer, Bristol Myers Squibb Company; Mr. Kare Schultz, President and Chief Executive Officer, Teva Pharmaceutical Industries Ltd. Hearing witnesses (pt. 2): Mr. Robert Bradway, Chairman and Chief Executive Officer, Amgen Inc.; Mr. Mark Trudeau, President and Chief Executive Officer, Mallinckrodt Pharmaceuticals; Mr. Thomas Kendris, U.S. Country President, Novartis AG. |
| Source of Description, Etc. Note: | Description based on online resource; title from PDF title page (govinfo, viewed July 6, 2021) |
| Date/Time and Place of an Event Note: | Date of hearing (pt. 1): 2020-09-30. Date of hearing (pt. 2): 2020-10-01. |